Glaukos Corp (GKOS)
49.26
+0.72
(+1.47%)
USD |
NYSE |
Mar 21, 16:00
49.26
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.358B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.68% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.368 |
| Price to Book Value | 4.449 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5309 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 69.57% |
News
Headline
Wire
Time (ET)
MT Newswires
02/23 13:24
MT Newswires
02/23 11:49
MT Newswires
02/22 16:12
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.58 | -- | |
| 02/22/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/22/2023 | -- | Results | Q4 2022 | -0.53 | -0.55 | 2.93% | |
| 11/02/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | -0.45 | -0.52 | 13.84% | |
| 08/03/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.83 | -0.44 | -89.61% |
*Estimated Date/Time
Earnings
Profile
Edit
| Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
| URL | https://www.glaukos.com |
| Investor Relations URL | https://investors.glaukos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 20, 2023.
Fundamentals
| Revenue (TTM) | 282.86M |
| Total Expenses (TTM) | 385.18M |
| Net Income (TTM) | -99.20M |
| Total Assets (Quarterly) | 1.002B |
| Total Liabilities (Quarterly) | 472.38M |
| Shareholders Equity (Quarterly) | 530.00M |
| Cash from Operations (TTM) | -33.08M |
| Cash from Investing (TTM) | 44.78M |
| Cash from Financing (TTM) | 6.251M |
Ratings
Profile
Edit
| Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
| URL | https://www.glaukos.com |
| Investor Relations URL | https://investors.glaukos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| GKOS Tweets |